FDA investigating malignancy risk with Zolgensma and Itvisma gene therapy
Published November 8, 2026 · Coverage November 1–7, 2026, Pacific · Lower priority
FDA said on November 6, 2026 that it has received postmarketing reports of malignancies after Zolgensma, including confirmed product-related insertional oncogenesis involving the Glioma-Associated Oncogene Homolog 1 (GLI1) gene, and that the risk applies to both onasemnogene abeparvovec products. FDA says the overall benefits of Zolgensma and Itvisma continue to outweigh their potential risks for their approved uses but it is evaluating whether regulatory action is appropriate, and recommends monitoring for tumor formation in patients and clinical trial participants receiving treatment with these products. FDA's Safety Communication of the same date says there have been no reported cases of neoplasia following Itvisma administration to date.
Background
Zolgensma is an adeno-associated virus vector-based gene therapy for spinal muscular atrophy, first approved on May 24, 2019; Itvisma, which contains the same vector and construct, was first approved on November 24, 2025. Their current U.S. prescribing information already lists a theoretical risk of tumorigenicity due to integration of the vector DNA into the genome, and Novartis, the sponsor, is conducting long-term follow-up safety studies.
Who this affects
Hospitals (including children's hospitals) and neuromuscular programs that administer or follow patients treated with Zolgensma (pediatric patients under 2) or Itvisma (adult and pediatric patients 2 years and older).
Why it matters
Treating programs may need to review follow-up and monitoring for treated patients. Inference.
Recommended action
- Route to pediatric neurology and gene therapy program leads
- Watch for labeling changes
Scope and timing
- Authority status
- Other (FDA safety communication; FDA says it is evaluating whether regulatory action is appropriate)
- Responsible owner
- Pharmacy; Pediatric Neurology
- Other dates
- FDA safety communication dated 2026-11-06 (the date printed on the page); the page's own metadata gives 2026-11-09 as its publication date
Not established
Whether FDA will take regulatory action or change the prescribing information is not established; FDA says it is evaluating whether regulatory action is appropriate and the adequacy of the current prescribing information.
Sources
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Compliance Sweep report →